Announced details
Treatment of macular atrophy associated with Stargardt disease
Lesion progression was significantly inhibited in patients with relatively small lesions at baseline
Dr. Kubota Ryo (窪田良), the Company's representative director, chairman, president and CEO, is scheduled to present at the organization's Annual Meeting
A leading global academic organization for ophthalmic research, with approximately 12,000 members in more than 75 countries
Colorado Convention Center (Denver, Colorado, U.S.)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
ARVO (Association for Research in Vision and Ophthalmology) 2026 Annual Meeting
| Item | Details |
|---|---|
| Names of Products / Services Covered | Emixustat hydrochloride (emixustat) |
| Counterparty | ARVO (Association for Research in Vision and Ophthalmology) |
| Counterparty overview | A leading global academic organization for ophthalmic research, with approximately 12,000 members in more than 75 countries |
| Relationship with the Company | Dr. Kubota Ryo (窪田良), the Company's representative director, chairman, president and CEO, is scheduled to present at the organization's Annual Meeting |
| Launch date | 7 May 2026, from 8:00 a.m. to 9:45 a.m. (scheduled; poster presentation) |
| Applicable area | Treatment of macular atrophy associated with Stargardt disease |
| Location | Colorado Convention Center (Denver, Colorado, U.S.) |
| Quantitative Effects | Lesion progression was significantly inhibited in patients with relatively small lesions at baseline |
| Source | ARVO (Association for Research in Vision and Ophthalmology) 2026 Annual Meeting |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The subgroup analysis results from the Phase 3 clinical trial will be presented at the ARVO 2026 Annual Meeting. Based on the analysis results, Kubota Vision, the Company's U.S. subsidiary, believes that emixustat could be a promising treatment option for patients with early-stage Stargardt disease and will continue to explore development opportunities.